Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Deloitte
Chinese Patent Office
McKinsey
Harvard Business School
Covington
Accenture
Johnson and Johnson
QuintilesIMS

Generated: April 23, 2018

DrugPatentWatch Database Preview

NEURACEQ Drug Profile

« Back to Dashboard

When do Neuraceq patents expire, and when can generic versions of Neuraceq launch?

Neuraceq is a drug marketed by Piramal Imaging and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-three patent family members in twenty-five countries.

The generic ingredient in NEURACEQ is florbetaben f-18. Additional details are available on the florbetaben f-18 profile page.
Summary for NEURACEQ
International Patents:33
US Patents:1
Applicants:1
NDAs:1
Bulk Api Vendors: 1
Clinical Trials: 2
Patent Applications: 8
Drug Prices:see details
DailyMed Link:NEURACEQ at DailyMed
Drug patent expirations by year for NEURACEQ
Synonyms for NEURACEQ
[18F]BAY 94-9172
18F-BAY94-9172
18F-Florbetaben
4-((1E)-2-(4-(2-(2-(2-((sup 18(f))fluoroethoxy)ethoxy)ethoxy)phenyl)eth-1-en-1-yl)-N-methylaniline
4-[(E)-2-[4-[2-[2-(2-fluoranylethoxy)ethoxy]ethoxy]phenyl]ethenyl]-N-methylaniline
4-{(E)-2-[4-(2-{2-[2-((18)F)fluoroethoxy]ethoxy}ethoxy)phenyl]ethenyl}-N-methylaniline
902143-01-5
AV-1
BAY 94-9172
BAY-949172
BAY94-9172
CHEBI:79033
CHEMBL566752
DB09148
DTXSID20238065
Florbetaben
florbetaben ((18)F)
Florbetaben ((sup 18)F)
Florbetaben (18F)
Florbetaben (18F) (JAN/INN)
Florbetaben (18F) [INN]
Florbetaben 18F [INN]
Florbetaben F 18
Florbetaben F-18
Florbetaben F18
Florbetaben f18 [USAN]
GTPL7769
Neuraceq (TN)
SCHEMBL11301755
TLA7312TOI
UNII-TLA7312TOI

US Patents and Regulatory Information for NEURACEQ

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Piramal Imaging NEURACEQ florbetaben f-18 SOLUTION;INTRAVENOUS 204677-001 Mar 19, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Piramal Imaging NEURACEQ florbetaben f-18 SOLUTION;INTRAVENOUS 204677-001 Mar 19, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for NEURACEQ

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,858,072 Stilbene derivatives and their use for binding and imaging amyloid plaques ➤ Try a Free Trial
8,465,726 Stilbene derivatives and their use for binding and imaging amyloid plaques ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for NEURACEQ

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0719 Netherlands ➤ Try a Free Trial PRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: EU/1/13/906 20140224
4 Finland ➤ Try a Free Trial
00719 Netherlands ➤ Try a Free Trial PRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: EU/1/13/906 20140220
647 Luxembourg ➤ Try a Free Trial PRODUCT NAME: FLORBETABEN (18F). FIRST REGISTRATION: 20140224
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Chinese Patent Office
Queensland Health
Johnson and Johnson
Harvard Business School
Cantor Fitzgerald
Cipla
Covington
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.